Cargando…

mTOR inhibitors: A novel class of anti-cancer agents

Detalles Bibliográficos
Autores principales:	Riaz, Haris, Riaz, Talha, Hussain, Syed A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3275452/ https://www.ncbi.nlm.nih.gov/pubmed/22214493 http://dx.doi.org/10.1186/1750-9378-7-1

Ejemplares similares

SMS reminders- future in self-care management of diabetes mellitus?
por: Riaz, Talha, et al.
Publicado: (2012)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Double agent mTOR
por: Danzer, Steve C.
Publicado: (2019)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Histone de-acetylase inhibitors: a promising future for cancer treatment?
por: Khan, Raja Samir, et al.
Publicado: (2013)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Derlin1 functions as an oncogene in cervical cancer via AKT/mTOR signaling pathway
por: Li, Ling, et al.
Publicado: (2019)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

Current development of the second generation of mTOR inhibitors as anticancer agents
por: Zhou, Hong-Yu, et al.
Publicado: (2012)

mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation
por: Osada, Naoki, et al.
Publicado: (2021)

Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
por: Mercer, Paul F, et al.
Publicado: (2016)

Methylnaltrexone Potentiates the Anti-Angiogenic Effects of mTOR Inhibitors
por: Singleton, Patrick A, et al.
Publicado: (2010)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition
por: Schneeweis, Christian, et al.
Publicado: (2022)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Dual mTOR Inhibition Is Required to Prevent TGF-β-Mediated Fibrosis: Implications for Scleroderma
por: Mitra, Anupam, et al.
Publicado: (2015)

Durable response to mTOR inhibition in a patient with relapsing papillary tumor of the pineal region
por: Belting, Mattias, et al.
Publicado: (2019)

Inhibition of mTOR signaling by rapamycin protects photoreceptors from degeneration in rd1 mice
por: Yang, Jia-Liang, et al.
Publicado: (2021)

Novel mTOR Inhibitor Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular Targeting Agents
por: Feng, Ying-Qi, et al.
Publicado: (2020)

mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target
por: Raychaudhuri, Smriti K, et al.
Publicado: (2014)

Morphoproteomics and biomedical analytics coincide with clinical outcomes in supporting a constant but variable role for the mTOR pathway in the biology of congenital hyperinsulinism of infancy
por: Brown, Robert E., et al.
Publicado: (2017)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

mTor Inhibitors for the Treatment of Endometriosis
por: Barra, Fabio, et al.
Publicado: (2018)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

Combinational therapy targeting the MET‐mTOR‐ROS loop disrupts mitochondrial autoregulatory machinery of liver cancer
por: Huang, Xing, et al.
Publicado: (2020)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

Lysosomal TMEM9‐LAMTOR4‐controlled mTOR signaling integrity is required for mammary tumorigenesis
por: Zhang, Shengzhe, et al.
Publicado: (2022)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

PI3K‐α/mTOR/BRD4 inhibitor alone or in combination with other anti‐virals blocks replication of SARS‐CoV‐2 and its variants of concern including Delta and Omicron
por: Acharya, Arpan, et al.
Publicado: (2022)

mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012)

Predicted mechanisms of resistance to mTOR inhibitors
por: Kurmasheva, R T, et al.
Publicado: (2006)

Practical considerations for the use of mTOR inhibitors
por: Diekmann, Fritz, et al.
Publicado: (2015)

Deptor: not only a mTOR inhibitor
por: Catena, Valeria, et al.
Publicado: (2017)

Role of mTOR Inhibitors in Kidney Disease
por: Kajiwara, Moto, et al.
Publicado: (2016)

mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
por: Exner, Samantha, et al.
Publicado: (2021)

Targeting mTOR for Anti-Aging and Anti-Cancer Therapy
por: Fu, Wencheng, et al.
Publicado: (2023)

Clinical development of mTOR inhibitors in breast cancer
por: Vicier, Cecile, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qntdmekhdchp3tf52ei75c79j2